Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Name: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Author: Inoue, Kenichi

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. — المؤلف: Inoue, Kenichi — Investigational new drugs 20200220

المؤلف: Inoue, Kenichi
النشر: Investigational new drugs 20200220
الوصف: 538-547 p.
الموضوعات: Adult؛ Aged؛ Antibodies, Monoclonal, Humanized؛ Antineoplastic Combined Chemotherapy Protocols؛ Breast Neoplasms؛ Female؛ Follow-Up Studies؛ Furans